The CITR goals are:
- To develop and implement standards for reporting islet/beta cell transplants and their outcome.
- To collect and compile data on all islet/beta cell transplants in human recipients performed in North America, as well as some European and Australian centers.
- To increase the safety of islet/beta cell transplantation by distributing electronically the pertinent information of submitted serious adverse event reports to all participating clinical centers in a timely fashion.
- To perform scientific analysis on islet/beta cell transplant data, with particular emphasis on:
- Safety of islet/beta cell transplant product and procedure and protocol-regulated treatment products
- Number of islet/beta cell transplants and retransplants performed, categorized by transplant institution, donor tissue source and handling, recipient category, transplant technique and site, and recipient treatment protocols
- Efficacy of islet/beta cell transplants as defined by standardized outcome measures and as determined by donor factors, recipient demographics, donor-recipient matching, islet/beta cell processing and product characteristics, transplant technique and site, recipient treatment, and post-transplant events
- To communicate comprehensive and current information on islet/beta cell transplantation to transplant institutions, the diabetes and general health care community, and the interested general public via the CITR web site (http://www.citregistry.org), publications, and presentations.
- To stimulate prospective and retrospective studies on emerging issues of importance.
This page is associated with a larger collection of pages. You can view them as a whole here.